Andrea Passalacqua has been elevated to the esteemed position of Vice President and General Manager at Alexion Pharmaceuticals, Inc. In this pivotal role, Passalacqua will spearhead country leadership responsibilities for Alexion Germany, taking charge of crucial aspects such as approval, reimbursement, and commercialization of cutting-edge rare disease medicines.
With over 17 years of experience in the biopharmaceutical industry, Passalacqua is well-known for his enthusiasm and results-driven leadership approach. He has a track record of driving good change and improving sustainability in the healthcare industry. Passalacqua's vast experience in strategic marketing, product launch strategies, and value-based pricing, notably in cancer and haematology treatments, positions him to have a long-term effect in his new job.
Particularly, Passalacqua previously worked as the Therapeutic Area Lead for Haematology and Nephrology International at Alexion Pharmaceuticals, where he was instrumental in assuring patient access and leading commercialization initiatives in Europe and other locations. His effective leadership abilities were important in uniting a cross-functional team behind the shared objective of offering new and accessible cures to those suffering from rare illnesses.
Before his tenure at Alexion, Passalacqua held key leadership positions at esteemed organisations such as Oncopeptides AB and EQRx, where he played pivotal roles in shaping organisational strategies and driving mission-driven initiatives aimed at fostering a more equitable and sustainable healthcare ecosystem.
Image Source: LinkedIn
